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(HCD), or Wilson’s disease (WD), 
is a severe chronic progressive dis-
ease with a genetically impaired 
metabolic disorder of copper. 
The ATP7B gene, located on the 
long arm of the 13th chromo-
some and encoding the P-type 
ATPase transmembrane protein, 
is responsible for the develop-
ment of HCD. Thanks to this, 
the copper molecule is integrated 
into apo-ceruloplasmin and ex-
cess copper is released into the 
bile. As a result of a mutation of 
the mentioned gene, the excretion 
of copper with bile is disrupted, 
the copper depots in hepatocytes 
are overloaded and excess copper 
enters the blood, followed by its 
deposition in target organs, espe-
cially in the subcortical structures 
of the brain [1, 2].
HCD is one of the few hered-
itary diseases that can be treated. 
In this disease, the main measures 
are aimed at limiting the intake of 
copper in the body and its accel-
erated elimination to prevent the 
accumulation and deposition of 
free toxic copper in the liver, brain 
and kidneys. Currently, there is 
no consensus on the choice of 
therapeutic target and therapeutic 
drug. To date, only two patho-
genetic therapy drugs have been 
registered in Ukraine: penicilla-
mine and zinc salts, while other 
alternative pathogenetic therapy 
drugs like the chelator Trientine 
and Tetrathiomolybdate, unfor-
tunately, are still not officially 
registered [3].
In 1956, J. M. Walshe pro-
posed penicillamine as a chelate 
agent for removing copper from 
the body [4]. To date, the world has 
accumulated extensive experience 
in the treatment of HCD with this 
drug. Despite its high efficiency, 
its use is often accompanied by 
severe complications [5, 6]. 
U. Merle et al. conducted a 
retrospective analysis of treatment 
results from 2000 to 2005 of 163 
patients with Wilson’s disease. 
137 (84.1 %) cases were classified as symptomatic, 26 (15.9 %) as 
asymptomatic, in the latter case, the diagnosis was made using 
family screening. Hepatic symptoms were noted in 58.9 % of pa-
tients, and neurological disorders prevailed in 33.7 %. 138 patients 
were treated with D-penicillamine, 9 with trientine, 13 with zinc 
salts. Three patients underwent a liver transplant. In most pa-
tients, the authors noted adverse pathological effects. These were 
predominantly patients who were 
treated with D-penicillamine. In 
this group, severe side effects were 
reported in more than 30 % of 
patients. In this regard, accord-
ing to the authors, D-penicilla-
mine should not be a drug that 
is preferred over zinc salts in the 
treatment of patients with neuro-
logical symptoms [6]. Due to the 
fact that the chelate drug peni-
cillamine often causes complica-
tions, especially at the beginning 
of treatment, it was necessary to 
find other, less toxic drugs for the 
treatment of HCD.
In 1961, G. Schouwink pro-
posed the use of a low-toxic drug 
such as zinc salts for the treatment 
of HCD [7, 8]. The extremely low 
toxicity of zinc is evidenced by the 
fact that for more than 100 years 
its salts have been used as antie-
pileptic drugs. The mechanism 
of the therapeutic effect of zinc is 
that zinc stimulates the produc-
tion of a metallothionine protein 
(endogenous chelating agent), 
which binds copper in entero-
cytes of the small intestine and 
liver hepatocytes and reduces its 
output into the portal circulation. 
Thus, copper ingested with food 
and bound by metallothionine in 
the intestine is not absorbed and 
excreted from the body with fe-
ces [9]. Recently, the number of 
studies on the effectiveness of the 
use of zinc preparations for the 
treatment of HCD has increased. 
The successful use of zinc prepa-
rations as a preventive therapy 
in presymptomatic patients, sup-
porting therapy after a course of 
chelation with penicillamine, as 
well as for the initial treatment 
of the neurological stage of the 
disease, is indicated by the results 
obtained by many authors [10, 11].
H. H. Franciska et al. on the 
basis of prolonged follow-up 
history (from 2 to 30 years, on 
average – 14 years) of zinc salt 
monotherapy in 17 patients with 
Wilson’s disease, came to the 
conclusion that such therapy is 
preferable for presymptomatic 
patients and patients with exclusively neurological manifes-
tations of the disease. For patients with exclusively hepatic 
manifestations or with a combination of them with neurological 
and hepatic manifestations, treatment with zinc salts can be 
prescribed only if the liver has no severe damage [12].
Hong Chang et al. monitored 89 children with Wilson’s 
disease between 1990 and 2008. Of these, 65 patients underwent 
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Abstract: The aim – to study the effectiveness of zinc salts in 
the treatment of patients with neurological forms of Wilson's 
disease (WD).
Materials and methods. The analysis of the treatment results 
of 128 patients with hepatocerebral degeneration (71 men and 
57 women) in the State Institution “Institute of Neurology, 
Psychiatry and Narcology of the National Academy of Medical 
Sciences of Ukraine” was carried out. At the time of hospitali-
zation, the age of patients ranged from 5 to 55 years, an average 
of 27.3 years, and at the time of debut of the disease – from 
1 year to 40 years, an average of 21.3 years. 33 patients under-
went monotherapy with zinc salts, 63 – combined therapy with 
small doses of penicillamine and zinc salts, 32 – monotherapy 
with penicillamine. 
Results. Because of the treatment, 67.1 % of patients showed 
an improvement in neuropsychiatric status: speech improved 
significantly, tremor of the extremities and the amplitude of 
hyperkinesis decreased, muscle tone decreased, and cognitive 
functions improved. According to the international two-level 
rating scale (UWDRS), the total pathology index decreased by 
21 points. Zinc salts are effective and low-toxic and can be the 
drug of choice in the treatment of patients with hepatocerebral 
degeneration in the pre-symptomatic stage of the disease, as 
well as at the stage of maintenance treatment, both as mon-
otherapy and in combination with penicillamine. However, 
zinc salts and penicillamine are not enough for the treatment 
and rehabilitation of patients with hepatocerebral degenera-
tion. Therefore, taking into account the clinical picture and the 
data of additional research methods, it is necessary to conduct 
courses of symptomatic treatment at least 1–2 times a year.
Conclusions. Thus, it can be noted that zinc salts are very ef-
fective and low toxic, and, therefore, can be the drug of choice 
in the treatment of patients with HCD in the pre-symptomatic 
stage of the disease, as well as at the stage of maintenance ther-
apy as a single drug, and in combination with penicillamine or 
other chelate drugs.
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combination therapy with small doses of D-penicillamine and 
large doses of zinc sulfate. In most (89.2 %) patients, the course 
of the disease was stable or with improvement. Complications 
were observed only in 10.8 %. Three (4.6 %) patients died. Four 
(6.2 %) patients underwent a liver transplant. Based on the lit-
erature and their own experience, the authors believe that com-
bination therapy with zinc salts and D-penicillamine deserves 
wider use due to its effectiveness, safety and availability [13].
There is no consensus on the advantages and disadvantages 
of zinc preparations compared to penicillamine. 
K. M. Weiss et al. after analyzing the results of treatment of 
288 patients with HCD, found that the frequency of discontinu-
ation of treatment with zinc preparations due to inefficiency and 
complications was higher than with penicillamine. The authors 
also noted that combination therapy with penicillamine and 
zinc preparations is associated with a high incidence of adverse 
outcomes. Indicators such as liver transplantation and death of 
patients were higher in the group receiving zinc monotherapy. 
According to the authors, zinc mono- and combination thera-
py are the method of choice in the treatment of asymptomatic 
patients and patients with neurological forms of the disease. In 
these patients, liver function should be periodically monitored. 
Patients with an abdominal hepatic form are preferable to pre-
scribe chelators such as penicillamine [14].
According to T. U. Hoogenraad, it is necessary to change 
the paradigm of treatment for HCD. Zinc preparations should 
be preferred in the treatment of this disease. He substantiates 
this provision by the fact that the pathogenesis of disease 
symptoms is caused not by the amount of deposited copper, 
but by the level of circulating free toxic copper. Therefore, 
according to the author, the aim of treatment should not be 
the excretion of copper in the urine, but the normalization of 
the level of free toxic copper. He regards the accumulation of 
copper in tissues as a sign of detoxification of free copper in 
the liver by metallothionein [15]. 
The aim of the work – to study the effectiveness of zinc salts 
in the treatment of patients with neurological forms of hepato-
cerebral degeneration.
2. Materials and methods
From 1992 to 2019 128 patients with Wilson’s disease were 
examined and treated at the clinic of the State Institution “In-
stitute of Neurology, Psychiatry and Narcology of the National 
Academy of Medical Sciences of Ukraine”. Of these, 36 people 
were observed in dynamics from one to three years. The diagno-
sis was made or confirmed based on a decrease in serum ceru-
loplasmin less than 20 mg/dl and an increase in urinary copper 
excretion of more than 100 μg/day, as well as the presence of 
Kaiser – Fleisher rings. In some patients, a genetic confirmation 
of the diagnosis was carried out, and neurological symptoms 
that were relatively specific for WD were taken into account, 
such as tremor in the form of a “heartbeat” and facial expres-
sions in the form of a pseudo-smile (risus sardonicus).
The Committee on Ethics and Deontology at the State Insti-
tution “Institute of Neurology, Psychiatry and Narcology of the 
National Academy of Medical Sciences of Ukraine” approved 
the work that was carried out in accordance with the Code of 
Ethics of the World Medical Association (Helsinki Declaration). 
All study participants signed informed consent. 
Of all 128 patients with WD, 71 were men, 57 women. For 
the period of hospitalization in the clinic, the age of the patients 
was in the range of 5–55 years, on average – 27.3±5.6 years. The 
age of patients at the time of the onset of the disease was 1 year – 
40 years, on average – 21.3±3.2 years.
The time from the onset of the first symptoms of the dis-
ease to the final diagnosis of WD, and, therefore, to the start of 
etiopathogenetic therapy, averaged 2.5 years and ranged from 
0–7 years. Depending on the clinical manifestations, patients 
were treated in various profiles of medical institutions with dif-
ferent diagnoses. The initial diagnosis of WD was determined 
in less than half of patients (47 people). In some patients, before 
the diagnosis of WD was established, the diagnosis changed 
3–4 times over several years.
In addition to the control of copper metabolism, the patient 
was performed MRI and MP spectroscopy of the brain and spi-
ral computed tomography of the abdominal organs in the clinic 
of the institute. With the help of ultrasound, hemodynamics of 
the brain and liver were studied. The functional state of the liver 
was evaluated using indicators such as total bilirubin (direct, 
indirect), alanine aminotransferase (ALT), aspartate amino-
transferase (AST), albumin, alkaline phosphatase (ALP) and 
gamma-glutamyl transpeptidase (GGT).
For an objective assessment of the patients’ condition and 
the dynamics of their neuropsychiatric status during treatment, 
the Unified Wilson’s Disease Rating Scale (UWDRS) was used, 
which allows us to evaluate the multisystem manifestations of 
WD disease. The first level assesses general disorders in four 
areas: liver, motor system, cognitive system and behaviour, as 
well as the musculoskeletal system. The second level evaluates 
neuropsychiatric dysfunctions; it has 14 points with a total pa-
thology score of 56 units [16]. 
3. Results
Of all 128 patients with HCD observed in the institute’s clinic, 
33 patients received monotherapy with zinc alone. For 11 out of 
33 patients, zinc monotherapy was prescribed due to intolerance 
to the chelator penicillamine. The dosage of the zinc prepara-
tion was 124 mg per tablet, taking 1–2 tablets 2–3 times a day 
15–20 minutes before meals. Six patients received zinc salt mono-
therapy because they were heterozygous siblings of patients and 
did not have a pronounced clinical picture of the disease. The 
dosage of zinc salts was 1 tablet, 3 times a day. 16 patients received 
maintenance monotherapy with zinc salts of 1 tablet 3 times a day 
after treatment with cuprenyl by this patient.
63 patients underwent combination therapy with small dos-
es of the penicillamine chelator and zinc salts (penicillamine 
250 mg in tablets, 1 tablet 2 times a day 1.5–2 hours after meals, 
zinc salts 1 tablet 3 times a day for 15–20 minutes before meals).
Analysis of the effectiveness of the treatment showed that 
67.1 % of patients had an improvement in the psychoneurologi-
cal status: speech improved significantly, tremor of the extrem-
ities and the amplitude of hyperkinesis decreased, tension of 
muscle tone decreased, and cognitive functions improved. Ac-
cording to the international two-level scale, the total pathology 
index decreased by 21 points.
Our clinical case can serve as an illustration of the effective-
ness of monotherapy for patients with HCD zinc salts.
Patient C, 30 years old, now complains of moderate weak-
ness throughout the body, joint pain, periodic cramps in the legs 
and fingers, constipation.
From the anamnesis, it is known that in 2000, for no ap-
parent reason, the body temperature rose to 40º and a diag-
nosis was made: chronic pyelonephritis. In 2006, handwriting 
imperceptibly worsened, tremors appeared, speech worsened, 
shakiness appeared while walking, convulsive laughter joined, 
and increased irritability appeared. He was diagnosed with Par-
kinson’s disease. In 2007, Kaiser-Fleischer rings were discovered 
and Wilson’s disease was diagnosed. A chelator penicillamine 
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at a dose of 250 mg was prescribed per day (1 tablet). On the 
third day of taking penicillamine in a patient, the temperature 
rose to 40º. While taking penicillamine, the patient’s condition 
worsened dramatically: the patient stopped walking, large-am-
plitude hyperkinesis of the upper extremities appeared, trans-
lational-rotational movements of the head, there was severe 
salivation, the sense of smell disappeared, and speech was 
sharply disturbed. In this regard, penicillamine was cancelled 
and monotherapy was prescribed with zinc salts of 1 tablet 
4 times a day. Only after 1.5 years of zinc treatment, the neu-
ropsychiatric status of the patient returned to baseline before 
taking penicillamine.
Currently, there is a slight lack of productivity of cognitive 
functions by the organic type. Muscle tone in the upper and 
lower extremities is increased in plastic type. Performs coordi-
nating tests with elements of easy intention. In the Romberg po-
sition, slight shakiness. On both sides, there are Kaiser-Fleischer 
rings. Long-term monotherapy with a zinc preparation not 
only stabilized the patient’s neuropsychiatric status, but also 
significantly improved the brain MRI picture. In 2008, 8 years 
after the onset of the disease, the patient underwent an MRI of 
the brain. On MRI tomograms, a bilateral pathological increase 
in the MR signal from subcortical structures and dentate nuclei 
of the cerebellar hemispheres was detected (Fig. 1, a), as well as 
an increase in the signal from the midbrain as a “panda head” 
(Fig. 1, b). In 2011, MR imaging of brain tomograms showed 
significant positive dynamics (Fig. 2, a, b). Ultrasound: endo-
thelial dysfunction 7.5 % (norm>10 %), diffuse changes in the 
liver, enlarged spleen, bilateral diffuse changes in the pyramidal 
parts of the renal parenchyma.
а  
b
Fig. 1. Brain MRI: T2-weighted images: a – an increase in the 
MR signal from the dentate nuclei of the cerebellar hemispheres; 
b – from the midbrain according to the type of “panda head”
а  
b
Fig. 2. MRI of the brain after 3 years: a – the absence of  
a pathological increase in the MR signal from the cerebellar 
hemispheres and from the subcortical structures; b – small focus 
of gliosis in the right cerebellar hemisphere
Analysis: 
– ceruloplasmin 0.044 units (Norm: 0.200–0,600 units); 
– copper in the blood 6.9 μmol/l (Norm: 13.4–24.4 μmol/l); 
– daily urinary copper excretion of 64.8 mcg/24h (Norm≤ 
≤60 mcg/24h); 
– creatine 109 μmol/L (Norm: 53–97 μmol/l); 
– ALT and AST are within normal limits.
As can be seen from this example, the patient gave a patho-
logical reaction to treatment with cuprenyl with a pronounced 
and persistent neurological deficit. With the help of monother-
apy with zinc salts, it was possible within 1.5 years to return the 
neurological status to the initial one, which was before taking 
cuprenyl. It should also be noted that with the help of zinc 
monotherapy it was possible not only to stabilize the dysfunc-
tion of the nervous system, but also to achieve a relative clinical 
and neurological recovery. However, according to ultrasound, 
structural pathological changes in the liver and kidneys remain, 
although there is a positive trend compared with previous data 
two years ago.
In this example, there is another question: “why did the pa-
tient give such a violent temperature and neurological reaction 
to the short-term administration of a relatively small dose of 
penicillamine (1 tablet)”? Most likely, this condition is caused 
primarily by the toxic effect of penicillamine itself, as well as by 
the large release of free toxic copper deposited in target organs 











superimposed on the patient’s initial kidney damage. After all, 
she had the onset of HCD at the age of 18 in 2000 was chronic 
pyelonephritis. This is also indicated by ultrasound data, where 
bilateral diffuse changes in the pyramidal sections of the renal 
parenchyma are noted. Another author [3] notes the influence 
of the initial pathology of the kidneys on the development of 
renal complications in the treatment of penicillin with patients 
with HCD in his extensive work [3].
4. Discussion and conclusions
Thus, it can be noted that zinc salts are very effective and 
low-toxic, and, therefore, can be the drug of choice in the 
treatment of patients with HCD in the pre-symptomatic stage 
of the disease, as well as at the stage of maintenance therapy, 
both as a single drug and in combination with penicillamine 
[17–19]. Given that the treatment of these patients lasts a 
lifetime, the fact that zinc preparations are several times 
cheaper than penicillamine and other chelating drugs is of 
great importance.
At the same time, it is necessary to take into account the 
fact that chelating preparations and zinc salts are aimed only at 
triggering pathogenetic mechanisms – normalization of copper 
metabolism in the body and cannot solve all the problems of 
the rehabilitation treatment of patients with HCD. The clinical 
picture of HCD is characterized by a large polymorphism in 
relation to both somatic and neurological manifestations, which 
is due to a cascade of metabolic disorders. In these patients, im-
portant life support systems are involved in the process. There-
fore, depending on the clinical manifestations and the data of 
additional research methods, patients also need symptomatic 
course treatment 1–2 times a year.
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